<DOC>
	<DOCNO>NCT00000810</DOCNO>
	<brief_summary>PRIMARY : To study safety tolerance delavirdine mesylate ( U-90152 ) monotherapy . To compare anti-HIV activity three blood concentration level agent nucleoside analog monotherapy , either zidovudine ( AZT ) didanosine ( ddI ) , base reduction HIV viral burden . SECONDARY : To use pharmacokinetic parameter assess relationship daily drug exposure antiviral activity toxicity U-90152 , AZT , ddI monotherapy . To assess anti-HIV activity use disease marker . Data suggest bisheteroarylpiperazines ( BHAPs ) delavirdine mesylate potent safe anti-HIV agent may different biological behavior currently available non-nucleoside RT inhibitor .</brief_summary>
	<brief_title>Randomized , Phase I/II , Dose-Ranging , Open-Label Trial Anti-HIV Activity Delavirdine Mesylate ( DLV ; U-90,152S )</brief_title>
	<detailed_description>Data suggest bisheteroarylpiperazines ( BHAPs ) delavirdine mesylate potent safe anti-HIV agent may different biological behavior currently available non-nucleoside RT inhibitor . Patients randomized receive U-90152 one three dos ( treatment arm I III ) either AZT ddI ( treatment arm IV ) . Patients arm IV AZT-naive receive AZT ; AZT-experienced receive ddI . Treatment continue 24 week . PER 12/22/94 AMENDMENT : All patient receive U-90152 start dose , attain one three target trough level .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : PCP prophylaxis . Topical antifungal agent , clotrimazole troche , nystatin oral suspension , topical ketoconazole , oral fluconazole . Acyclovir ( &lt; = 1000 mg/day ) maintenance therapy herpes simplex virus . Recombinant erythropoietin GCSF . Antibiotics bacterial infection , unless specifically exclude . Symptomatic treatment antipyretic , analgesic , nonsteroidal antiinflammatory agent , antiemetic . Antacids . Patients must : HIV1 infection . CD4 count 200 500 cells/mm3 . Either prior antiretroviral therapy discontinue AZT monotherapy 3 week prior study entry . NOTE : Half patient antiretroviral naive . Prior Medication : Allowed : Prior AZT . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy minimal Kaposi 's sarcoma . Concurrent Medication : Excluded : Rifabutin . Rifampin . Terfenadine . Astemizole . Loratadine . Trifluoperazine . Piperazine citrate . Any acute chronic therapy CMV , MAC , toxoplasmosis , disseminate fungal infection . Nonstudy antiretroviral therapy , interferon , biologic response modifier , HIV vaccine . Systemic corticosteroids 21 consecutive day . Foscarnet . Systemic cytotoxic chemotherapy malignancy . Patients follow prior condition exclude : History pancreatitis ( patient receive prior AZT ) . History grade 2 bad peripheral neuropathy ( patient receive prior AZT ) . History hypersensitivity BHAP compound ( e.g. , trifluoperazine Stelazine , piperazine citrate Antepar ) . Prior Medication : Excluded within 30 day prior study entry : Any investigational medication . Interferon . Interleukin . Rifabutin . Rifampin . Terfenadine . Astemizole . Loratadine . Trifluoperazine . Piperazine citrate . Excluded time : Prior ddI , ddC , d4T , 3TC . Prior foscarnet . Prior BHAP compound nonnucleoside RT inhibitor . Active substance abuse interfere compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Zidovudine</keyword>
</DOC>